| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
PrEP HIV Monitoring, Female Panel
Test Code37138
CPT Codes
87389, 82565, 84702, 86592, 87491, 87591
Includes
hCG, Total, Quantitative
Creatinine
HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
RPR (Diagnosis) with Reflex to Titer and Confirmatory Testing
Chlamydia/Neisseria gonorrhoeae RNA, TMA, Urogenital
If HIV Antigen and Antibody, 4th Generation Screen is Repeatedly Reactive, then HIV-1/2 Antibody Differentiation will be performed at an additional charge (CPT code(s): 86701, 86702).
If HIV-1/2 Antibody Differentiation is Indeterminate or Negative, then HIV-1 RNA, Qualitative, TMA will be performed at an additional charge (CPT code(s): 87535).
If RPR screen is reactive, then RPR Titer and Fluorescent Treponemal Antibody (FTA) Confirmatory testing will be performed at an additional charge (CPT code(s): 86593, 86780).
Creatinine
HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
RPR (Diagnosis) with Reflex to Titer and Confirmatory Testing
Chlamydia/Neisseria gonorrhoeae RNA, TMA, Urogenital
If HIV Antigen and Antibody, 4th Generation Screen is Repeatedly Reactive, then HIV-1/2 Antibody Differentiation will be performed at an additional charge (CPT code(s): 86701, 86702).
If HIV-1/2 Antibody Differentiation is Indeterminate or Negative, then HIV-1 RNA, Qualitative, TMA will be performed at an additional charge (CPT code(s): 87535).
If RPR screen is reactive, then RPR Titer and Fluorescent Treponemal Antibody (FTA) Confirmatory testing will be performed at an additional charge (CPT code(s): 86593, 86780).
Preferred Specimen
5 mL serum collected in each of two separate Serum Separator Tubes (SST®) and urine collected in an APTIMA® Urine Collection Tube
Patient Preparation
Urine: Patient should not have urinated within one hour prior to collection
Minimum Volume
3 mL serum (x2)
Other Acceptable Specimens
5 mL serum collected in each of two separate Serum Separator Tubes (SST®) and
Endocervical or urethral swab collected in APTIMA® Combo 2 Assay Unisex Swab Specimen Collection Kit, or Vaginal swabs in the APTIMA® Combo 2 Assay Vaginal Swab Collection Kit or Multitest Collection
Endocervical or urethral swab collected in APTIMA® Combo 2 Assay Unisex Swab Specimen Collection Kit, or Vaginal swabs in the APTIMA® Combo 2 Assay Vaginal Swab Collection Kit or Multitest Collection
Instructions
HIV Serum: Spun serum separator tubes may be submitted at room temperature or refrigerated unopened without transfer to a plastic, screw-cap vial.
Submitted tubes must be labeled with patient identifier and submitted only for HIV testing.
Submitted tubes must be labeled with patient identifier and submitted only for HIV testing.
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Serum Separator Tubes (SST®)
Room temperature: 72 hours
Refrigerated: 5 days
Frozen: 21 days
Urine
Room temperature: 30 days
Refrigerated: 30 days
Frozen: 1 year
Swabs
Room temperature: 60 days
Refrigerated: 60 days
Frozen: 1 year
Room temperature: 72 hours
Refrigerated: 5 days
Frozen: 21 days
Urine
Room temperature: 30 days
Refrigerated: 30 days
Frozen: 1 year
Swabs
Room temperature: 60 days
Refrigerated: 60 days
Frozen: 1 year
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Grossly lipemic • Grossly icteric • Plasma • Red-top tube (no gel) • Frozen serum separator tube (SST)
Methodology
See individual tests
Setup Schedule
Set up: Mon-Sat; Report available: 2-5 days
Clinical Significance
Pre-exposure prophylaxis (PrEP) is a protocol that decreases the risk of acquiring HIV infection in people who do not have HIV, but are at high risk of becoming infected. PrEP involves taking a medication to prevent new HIV infection. All persons who are under consideration for PrEP should undergo baseline and monitoring laboratory testing, in order to identify those who are at risk for harm from the therapy and require close monitoring.
Laboratory testing for PrEP includes a baseline panel to rule out HIV, HBV and HCV infections; sexually transmitted infections (syphilis, chlamydia and gonorrhea); and renal dysfunction that would make the PrEP medication unsafe. In female patients, a test is also performed to rule out pregnancy. After PrEP is initiated, quarterly laboratory monitoring is indicated to rule out HIV infection, sexually transmitted infections, renal dysfunction and pregnancy (in females).
Laboratory testing for PrEP includes a baseline panel to rule out HIV, HBV and HCV infections; sexually transmitted infections (syphilis, chlamydia and gonorrhea); and renal dysfunction that would make the PrEP medication unsafe. In female patients, a test is also performed to rule out pregnancy. After PrEP is initiated, quarterly laboratory monitoring is indicated to rule out HIV infection, sexually transmitted infections, renal dysfunction and pregnancy (in females).
